CANG vs AUTL

For growth investors, Autolus Therapeutics plc (AUTL) is the stronger pick with 496.

0% revenue growth year-over-year, versus -52. 7% for Cango Inc. (CANG). Cango Inc. (CANG) offers the better valuation at 5. 8x trailing P/E, making it the more compelling value choice. Analysts rate Cango Inc. (CANG) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Cango Inc.

(CANG) delivered a total return of -13. 9%, compared to -66. 7% for Autolus Therapeutics plc (AUTL). Over 10 years, the gap is even starker: CANG returned -44. 7% versus AUTL's -93. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Autolus Therapeutics plc (AUTL) is the lower-risk stock at 1.

95β versus Cango Inc. 's 2. 25β — meaning CANG is approximately 15% more volatile than AUTL relative to the S&P 500. On balance sheet safety, Cango Inc. (CANG) carries a lower debt/equity ratio of 4% versus 12% for Autolus Therapeutics plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Autolus Therapeutics plc (AUTL) is pulling ahead at 496.

0% versus -52. 7% for Cango Inc. (CANG). On earnings-per-share growth, the picture is similar: Cango Inc. grew EPS 960. 0% year-over-year, compared to 27. 5% for Autolus Therapeutics plc. Over a 3-year CAGR, AUTL leads at 88. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Cango Inc.

(CANG) is the more profitable company, earning 37. 3% net margin versus -21. 8% for Autolus Therapeutics plc — meaning it keeps 37. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CANG leads at 22. 2% versus -23. 9% for AUTL. At the gross margin level — before operating expenses — CANG leads at 55. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Autolus Therapeutics plc (AUTL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding.

Cango Inc. (CANG) carries a higher beta of 2. 25 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AUTL: -93. 2%, CANG: -44. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (CANG (Consumer Cyclical) and AUTL (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: CANG is a small-cap deep-value stock; AUTL is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.